BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

BioN­Tech, MediLink to re­sume tri­al en­roll­ment for HER3 an­ti­body-drug con­ju­gate af­ter FDA pause

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause